Sildenafil, the active ingredient in the popular erectile dysfunction drug Viagra, may have a role in combating cancer's spread, according to new research from the Weizmann Institute of Science in Israel. Scientists found that in laboratory tests, the drug interfered with cancer cells' ability to access cholesterol, a vital nutrient for their survival and proliferation.
Disruption of Cholesterol Access
The study, published in Cancer Research, explored how sildenafil affects various cancer cell types, including those from breast, lung, and colon cancers. In human cancer cells cultured in the lab, sildenafil was observed to slow their movement and multiplication, with the most significant impact seen in breast cancer cells. Lung and colon cancer cells also demonstrated notable responses.
To further investigate, researchers administered sildenafil to mice with cancer. The drug significantly reduced the spread of tumors to the lungs, in some cases by more than half, while having a minimal effect on the primary tumors themselves.
Scientists explained that sildenafil works by blocking cholesterol from being released into cancer cells. Cholesterol is essential for cancer cells to build new membranes, a process necessary for growth and spread.
Real-World Patient Data Analysis
In addition to laboratory experiments, the research team analyzed health records from Clalit Health Services in Israel, encompassing nearly 5 million individuals over a 20-year period. They compared cancer patients who had used sildenafil with those who had not, controlling for factors such as age, socioeconomic status, and other medications.
The analysis revealed that cancer patients who took sildenafil at least three times in the six months prior to their diagnosis had a 26 percent lower risk of death within five years compared to non-users. The study also noted that cancer patients taking sildenafil alongside statins, a class of drugs used to lower cholesterol, experienced an even greater reduction in mortality risk, at 32 percent.
For diabetic patients, who are more likely to have documented sildenafil use, the combination of sildenafil and statins was associated with a 41 percent reduced risk of death. The observed survival advantage appeared to be dose-dependent, with patients receiving three or more sildenafil dispensations showing a significant benefit, unlike those with fewer prescriptions.
Broader Implications
Dr. Ayelet Erez, a physician-scientist who led the study, stated that the findings uncover a new biological pathway that could potentially be utilized to hinder cancer's ability to spread. She emphasized that cancer biology is influenced not only by mutations within tumor cells but also by a patient's metabolic state and the medications they are already taking for other conditions.
While the research is in its early stages and does not yet prove that sildenafil can treat cancer, scientists believe it opens a promising avenue for developing new therapeutic strategies. The findings also highlight the importance of a holistic approach to patient care, considering all aspects of a patient's health and treatments.